论文部分内容阅读
目的：分析前列地尔联合舒洛地特治疗糖尿病足的临床效果。方法对2007年1月至2013年5月于我院收治的64例糖尿足患者，随机分为研究组和对照组，在控制血糖、局部换药的同时，对照组：口服双嘧达莫50m g，3次/日，低分子右旋糖酐注射液500m l，1次/日静滴，2周为1疗程；研究组：前列地尔(凯时)10μg溶于生理盐水250ml中静脉滴注，1次/日；舒洛地特600LSU/2ml,肌注，每日1次，20天后改为口服，每次1粒，每日2次，2周为1疗程。两组病人治疗2个疗程后进行疗效评定。结果研究组治疗后纤维蛋白原、全血粘度、血液粘度、和红细胞压积较治疗前明显降低，P<0.05；研究组治疗后纤维蛋白原、全血粘度、血液粘度、和红细胞压积较对照组治疗后明显降低，P<0.05；研究组显效率和总有效率明显高于对照组，P<0.05。结论前列地尔联合舒洛地特治疗糖尿病足，能降低血液粘度，改善微循环，促进糖尿病足的愈合。“,”Objective To analyze the therapeutic effect of Alprostadil and Sulodexide for treating diabetic foot. Methods 64 cases with diabetic foot in our hospital from Jan. 2007 to Jan. 2013, were divided into control group and research group. Control group: oral administration dipyridamole 50mg, tid; intravenous drip low molecular dextran 500ml, qd. Research group: intravenous drip Alprostadil 10mg, qd; intramuscular Sulodexide 600LSU/2ml, qd. The therapeutic effect of al patients was evaluated after two course of treatment. Results The fibrinogen, whole blood viscosity, blood viscosity, and hematokrit after treatment lower than its’ prior treatment in research group, P<0.05; the fibrinogen, whole blood viscosity, blood viscosity, and hematokrit in research group after treatment lower than its’ in control group after treatment, P<0.05; the apparent effective rate and total effective rate in research group apparently higher than its’ in control group, P<0.05. Conclusion it’s effective treating diabetic foot with Alprostadil and Sulodexide.